<?xml version="1.0"?>
<case>
<name>GenRx Pty Limited v Les Laboratoires Servier [2007] FCA 442 (26 March 2007)</name>
<AustLII>http://www.austlii.edu.au/au/cases/cth/FCA/2007/442.html</AustLII>
<citphrases>
<citphrase id="cp0.0" type=cited from="[2006] HCA 46">australian broadcasting corporation v o'neill  defamation</citphrase>
<citphrase id="cp0.1" type=cited from="[2006] HCA 46">injunctions</citphrase>
<citphrase id="cp0.2" type=cited from="[2006] HCA 46">interlocutory injunctions</citphrase>
<citphrase id="cp0.3" type=cited from="[2006] HCA 46">interlocutory injunction to restrain publication</citphrase>
<citphrase id="cp0.4" type=cited from="[2006] HCA 46">appellant restrained from broadcasting documentary film making allegations including that respondent suspected of having committed notorious unsolved crime</citphrase>
<citphrase id="cp0.5" type=cited from="[2006] HCA 46">principles on which interlocutory injunction to restrain publication granted</citphrase>
<citphrase id="cp0.6" type=cited from="[2006] HCA 46">relevance of "flexible" or "rigid" approaches to granting interlocutory injunctions</citphrase>
<citphrase id="cp0.7" type=cited from="[2006] HCA 46">significance of value of free speech</citphrase>
<citphrase id="cp0.8" type=cited from="[2006] HCA 46">significance of avoiding "trial by media"</citphrase>
<citphrase id="cp0.9" type=cited from="[2006] HCA 46">whether relevant that only nominal damages likely to be awarded</citphrase>
<citphrase id="cp0.10" type=cited from="[2006] HCA 46">significance of status of respondent as convicted life prisoner.  injunctions</citphrase>
<citphrase id="cp0.11" type=cited from="[2006] HCA 46">interlocutory injunctions</citphrase>
<citphrase id="cp0.12" type=cited from="[2006] HCA 46">defamation</citphrase>
<citphrase id="cp0.13" type=cited from="[2006] HCA 46">whether general principles governing grant of interlocutory injunctions to restrain wrongs apply to interlocutory applications to restrain publication of allegedly defamatory matter</citphrase>
<citphrase id="cp0.14" type=cited from="[2006] HCA 46">relationship between beecham group ltd v bristol laboratories pty ltd [1968] hca 1 ; (1968) 118 clr 618 and american cyanamid co v ethicon ltd [1975] ukhl 1 ; [1975] ac 396</citphrase>
<citphrase id="cp0.15" type=cited from="[2006] HCA 46">whether respondent had made out an entitlement to an interlocutory injunction within the principles established by beecham</citphrase>
<citphrase id="cp0.16" type=cited from="[2006] HCA 46">whether full court and primary judge shown to have erred in granting of interlocutory injunction.  defamation</citphrase>
<citphrase id="cp0.17" type=cited from="[2006] HCA 46">injunctions</citphrase>
<citphrase id="cp0.18" type=cited from="[2006] HCA 46">jurisdiction to grant interlocutory injunction to restrain publication of allegedly defamatory matter</citphrase>
<citphrase id="cp0.19" type=cited from="[2006] HCA 46">nature of equitable jurisdiction to grant injunctions to restrain publication</citphrase>
<citphrase id="cp0.20" type=cited from="[2006] HCA 46">effect of common law procedure act 1854 (uk)</citphrase>
<citphrase id="cp0.21" type=cited from="[2006] HCA 46">effect of judicature act 1873 (uk).  appeal</citphrase>
<citphrase id="cp0.22" type=cited from="[2006] HCA 46">interlocutory injunction in defamation proceedings</citphrase>
<citphrase id="cp0.23" type=cited from="[2006] HCA 46">necessity of demonstrating error in order to justify intervention by high court</citphrase>
<citphrase id="cp0.24" type=cited from="[2006] HCA 46">whether error shown in approach and conclusion of full court and primary judge.  defamation</citphrase>
<citphrase id="cp0.25" type=cited from="[2006] HCA 46">defences</citphrase>
<citphrase id="cp0.26" type=cited from="[2006] HCA 46">justification</citphrase>
<citphrase id="cp0.27" type=cited from="[2006] HCA 46">whether avoiding "trial by media" relevant to determination of "public benefit" required by defamation act 1957 (tas) s 15.</citphrase>
<citphrase id="cp1.0" type=cited from="[1968] HCA 1">injunctions</citphrase>
<citphrase id="cp1.1" type=cited from="[1968] HCA 1">patents</citphrase>
<citphrase id="cp1.2" type=cited from="[1968] HCA 1">action for infringement</citphrase>
<citphrase id="cp1.3" type=cited from="[1968] HCA 1">interlocutory injunction</citphrase>
<citphrase id="cp1.4" type=cited from="[1968] HCA 1">principles governing grant or refusal.</citphrase>
<citphrase id="cp2.0" type=citing from="[2008] FCA 607">trade practices</citphrase>
<citphrase id="cp2.1" type=citing from="[2008] FCA 607">misleading and deceptive conduct under s 52 of the trade practices act 1974 (cth)</citphrase>
<citphrase id="cp2.2" type=citing from="[2008] FCA 607">stamp distributed to be applied to doctors' prescriptions containing statement "brand substitution not permitted for coversyl"</citphrase>
<citphrase id="cp2.3" type=citing from="[2008] FCA 607">publication of four advertisements in medical publications</citphrase>
<citphrase id="cp2.4" type=citing from="[2008] FCA 607">advertisements variously contained other statements regarding drug</citphrase>
<citphrase id="cp2.5" type=citing from="[2008] FCA 607">each statement considered</citphrase>
<citphrase id="cp2.6" type=citing from="[2008] FCA 607">class of persons to whom stamp representations made includes doctors, pharmacists and patients</citphrase>
<citphrase id="cp2.7" type=citing from="[2008] FCA 607">ordinary and reasonable doctors would not be misled by stamp</citphrase>
<citphrase id="cp2.8" type=citing from="[2008] FCA 607">stamp could cause confusion for and mislead pharmacists and patients</citphrase>
<citphrase id="cp2.9" type=citing from="[2008] FCA 607">servier liable for representations contained in stamp by distributing stamp and accessorially liable for use by doctors</citphrase>
<citphrase id="cp2.10" type=citing from="[2008] FCA 607">representations in advertisements made to doctors</citphrase>
<citphrase id="cp2.11" type=citing from="[2008] FCA 607">representations do not misleadingly refer to government regulatory considerations</citphrase>
<citphrase id="cp2.12" type=citing from="[2008] FCA 607">representation "tick the box" in advertisements not misleading in context of generic substitution</citphrase>
<citphrase id="cp2.13" type=citing from="[2008] FCA 607">representations as to "improved stability" misleading</citphrase>
<citphrase id="cp2.14" type=citing from="[2008] FCA 607">representations as to "minimise patient confusion" not misleading</citphrase>
<citphrase id="cp2.15" type=citing from="[2008] FCA 607">statement that product "now indicated" for coronary artery disease misleading where indication several years old</citphrase>
<citphrase id="cp2.16" type=citing from="[2008] FCA 607">use of "now" implies indication is new</citphrase>
<citphrase id="cp2.17" type=citing from="[2008] FCA 607">contravention of s 52</citphrase>
</citphrases>
<citances>
<sentence id="cs0" from="[2008] FCA 607">51 After GenRx sought interlocutory relief in these proceedings ( GenRx Pty Limited v Les Laboratoires Servier [2007] FCA 442 ; (2007) 71 IPR 606) , Servier undertook not to distribute the stamp further and has issued to doctors a second form of stamp. The text of that stamp, about which GenRx does not complain, is:</sentence>
</citances>
<legistitles>
<title id="l0">FEDERAL COURT RULES </title>
</legistitles>
</case>